PsiOxus Therapeutics Ltd., an Oxford, UK-based oncolytic immuno-oncology company, closed a £25m Series C financing round.
The round was led by founding investor Imperial Innovations with participation from current investors Invesco, SROne (investment arm of GlaxoSmithKline), Lundbeckfond Ventures and Mercia Technologies and new investor Woodford Investment Management (via the recently formed Woodford Patient Capital Trust).
Led by Dr John Beadle, CEO, PsiOxus is a development stage biotechnology company advancing enadenotucirev, an oncolytic virus that has been shown in phase I clinical trials to reach and selectively infect cancer cells when administered by intravenous infusion.
The company intends to use the funds to progress its lead clinical candidate, enadenotucirev (conducting a phase I clinical study combining enadenotucirev and an immune-checkpoint inhibitor in patients with metastatic colorectal cancer), and a pipeline of follow-on oncolytic programs from the antibody “armed” series of AbEnAd viruses.
FinSMEs
19/05/2015